Skip to main content
. 2006 Dec;34(6):303–309. doi: 10.1007/s15010-006-6619-x

Table 2.

Pooled mean and key percentiles of resistance densities (RD = number of resistant isolates/1,000 pd and antimicrobial resistance proportions (RP = number of resistant isolates/100 tested isolates) and) of selected pathogens from SARI ICUs (n = 40), 2001–2004 and temporal differences in RD between 2001 vs 2004 (data of 34 SARI ICUs providing resistance data from 2001 through 2004).

Pathogen Resistant to Rooled RD (RP%) of all SARI-ICUs 01/2001–12/2004 RD from 34 SARI ICUs providing resistance data from 2001 to 2004
No tested Pooled mean 25% percentile Median 75% percentile No ICUs** in analysis Year 2001 median RD Year 2004 median RD No. of ICUs with an increase/decrease/no change of RD from 2001 to 2004
S. aureus MethiciLLin 12,238 4.4 (21.5%) 1.92 (12.0%) 3.34 (21.2%) 4.8 (32.1%) 30 2.7 3.7 18/12/0
E. faecalis Vancomycin 5,371 0.0 (0.1%) 0.0 (0%) 0.0 0.0 27 0 0 0/1/26
E. faecium Vancomycin 1,945 0.1 (2.6%) 0.0 (0%) 0.0 0.1 (3.3%) 11 0 0 2/3/6
K. pneumoniae Third gen. cephalosporins 3,205 0.4 (7.5%) 0.0 (0%) 0.1 (2.0%) 0.3 (6.5%)) 20 0 0.2 9/3/8
E. coli Third gen. cephalosporins 8,110 0.3 (2.3%) 0.0 (0%) 0.2 (1.7%) 0.5 (3.5%) 27 0 0.2 14/6/7*
Ciprofloxacin 7,152 1.5 (12.3%) 0.5 (8.3%) 1.3 (12.0%) 2.0 (16.6%) 27 1.1 1.8 20/5/2*
P. aeruginosa Imipenem 4,442 1.7 (23.2%) 0.4 (8.4%) 1.1 (18.6%) 2.4 (26.6%) 21 2.0 1.1 5/16/0
Ceftazidime 5,005 1.3 (15.6%) 0.4 (6.5%) 1.0 (11.1%) 2.0 (20.5%) 26 0.6 1.1 14/12/0
Ciprofloxacin 5,009 1.5 (17.6%) 0.5 (8.6%) 1.2 (15.4%) 2.2 (26.2%) 26 1.2 1.0 10/14/2
Piperacillin-tazobactam 4,058 1.5 (22.0%) 0.3 (8.7%) 0.0 (15.7%) 3.5 (36.7%) 21 1.6 1.4 9/12/0

“Resistant to third generation cephalosporins” i.e. cefotaxim or ceftiaxon or ceftazidime; *if p-value < 0.05 by Wilcoxon signed-rank test for paired samples 2001 vs 2004; ** ICUs with on at least ten isolates tested per antimicrobial/pathogen per year